These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
ý
|
Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
¨
|
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
Minnesota
|
|
41-0948415
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
2001 Theurer Boulevard
Winona, Minnesota
|
|
55987-0978
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
Large Accelerated Filer
|
|
ý
|
|
Accelerated Filer
|
|
¨
|
|
|
|
|
|||
Non-accelerated Filer
|
|
¨
(Do not check if a smaller reporting company)
|
|
Smaller Reporting Company
|
|
¨
|
Class
|
|
Outstanding at April 9, 2013
|
Common Stock, par value $.01 per share
|
|
296,686,927
|
|
|
|
|
|
|
Page No.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|||
Assets
|
March 31, 2013
|
|
December 31, 2012
|
|||
Current assets:
|
|
|
|
|||
Cash and cash equivalents
|
$
|
159,240
|
|
|
79,611
|
|
Marketable securities
|
417
|
|
|
354
|
|
|
Trade accounts receivable, net of allowance for doubtful accounts of $6,728
|
418,733
|
|
|
372,159
|
|
|
Inventories
|
700,484
|
|
|
715,383
|
|
|
Deferred income tax assets
|
14,079
|
|
|
14,420
|
|
|
Other current assets
|
83,883
|
|
|
97,361
|
|
|
Prepaid income taxes
|
—
|
|
|
7,368
|
|
|
Total current assets
|
1,376,836
|
|
|
1,286,656
|
|
|
|
|
|
|
|||
Property and equipment, less accumulated depreciation
|
555,734
|
|
|
516,427
|
|
|
Other assets, net
|
12,726
|
|
|
12,749
|
|
|
|
|
|
|
|||
Total assets
|
$
|
1,945,296
|
|
|
1,815,832
|
|
|
|
|
|
|||
Liabilities and Stockholders’ Equity
|
|
|
|
|||
Current liabilities:
|
|
|
|
|||
Accounts payable
|
$
|
75,327
|
|
|
78,019
|
|
Accrued expenses
|
126,091
|
|
|
126,155
|
|
|
Income taxes payable
|
51,679
|
|
|
—
|
|
|
Total current liabilities
|
253,097
|
|
|
204,174
|
|
|
|
|
|
|
|||
Deferred income tax liabilities
|
51,336
|
|
|
51,298
|
|
|
|
|
|
|
|||
Stockholders' equity:
|
|
|
|
|||
Preferred stock, 5,000,000 shares authorized
|
—
|
|
|
—
|
|
|
Common stock, 400,000,000 shares authorized, 296,686,427 and 296,564,382 shares issued and outstanding, respectively
|
2,967
|
|
|
2,966
|
|
|
Additional paid-in capital
|
66,560
|
|
|
61,436
|
|
|
Retained earnings
|
1,556,987
|
|
|
1,477,601
|
|
|
Accumulated other comprehensive income
|
14,349
|
|
|
18,357
|
|
|
Total stockholders' equity
|
1,640,863
|
|
|
1,560,360
|
|
|
Total liabilities and stockholders' equity
|
$
|
1,945,296
|
|
|
1,815,832
|
|
|
(Unaudited)
|
|||||
|
Three months ended
March 31, |
|||||
|
2013
|
|
2012
|
|||
Net sales
|
$
|
806,326
|
|
|
768,875
|
|
|
|
|
|
|||
Cost of sales
|
384,446
|
|
|
374,698
|
|
|
Gross profit
|
421,880
|
|
|
394,177
|
|
|
|
|
|
|
|||
Operating and administrative expenses
|
247,334
|
|
|
232,970
|
|
|
(Gain) loss on sale of property and equipment
|
(213
|
)
|
|
174
|
|
|
Operating income
|
174,759
|
|
|
161,033
|
|
|
|
|
|
|
|||
Interest income
|
447
|
|
|
96
|
|
|
Interest expense
|
(34
|
)
|
|
—
|
|
|
|
|
|
|
|||
Earnings before income taxes
|
175,172
|
|
|
161,129
|
|
|
|
|
|
|
|||
Income tax expense
|
66,124
|
|
|
60,935
|
|
|
|
|
|
|
|||
Net earnings
|
$
|
109,048
|
|
|
100,194
|
|
|
|
|
|
|||
Basic net earnings per share
|
$
|
0.37
|
|
|
0.34
|
|
|
|
|
|
|||
Diluted net earnings per share
|
$
|
0.37
|
|
|
0.34
|
|
|
|
|
|
|||
Basic weighted average shares outstanding
|
296,643
|
|
|
295,538
|
|
|
|
|
|
|
|||
Diluted weighted average shares outstanding
|
297,652
|
|
|
296,927
|
|
|
|
(Unaudited)
|
|||||
|
|
Three months ended
March 31, |
|||||
|
|
2013
|
|
2012
|
|||
Net earnings
|
|
$
|
109,048
|
|
|
100,194
|
|
Other comprehensive income (loss), net of tax:
|
|
|
|
|
|||
Foreign currency translation adjustments (net of tax of $0 in 2013 and 2012)
|
|
(4,072
|
)
|
|
2,940
|
|
|
Change in marketable securities (net of tax of $0 in 2013 and 2012)
|
|
63
|
|
|
23
|
|
|
Comprehensive income
|
|
$
|
105,039
|
|
|
103,157
|
|
|
(Unaudited)
|
|||||
|
Three months ended
March 31, |
|||||
|
2013
|
|
2012
|
|||
Cash flows from operating activities:
|
|
|
|
|||
Net earnings
|
$
|
109,048
|
|
|
100,194
|
|
Adjustments to reconcile net earnings to net cash provided by operating activities:
|
|
|
|
|||
Depreciation of property and equipment
|
15,152
|
|
|
12,415
|
|
|
(Gain) loss on sale of property and equipment
|
(213
|
)
|
|
174
|
|
|
Bad debt expense
|
2,045
|
|
|
2,329
|
|
|
Deferred income taxes
|
379
|
|
|
1,863
|
|
|
Stock based compensation
|
1,350
|
|
|
1,050
|
|
|
Excess tax benefits from stock based compensation
|
(954
|
)
|
|
—
|
|
|
Amortization of non-compete agreements
|
26
|
|
|
148
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|||
Trade accounts receivable
|
(48,619
|
)
|
|
(50,617
|
)
|
|
Inventories
|
14,899
|
|
|
(1,734
|
)
|
|
Other current assets
|
13,478
|
|
|
15,536
|
|
|
Accounts payable
|
(2,692
|
)
|
|
2,334
|
|
|
Accrued expenses
|
(64
|
)
|
|
1,134
|
|
|
Income taxes
|
60,001
|
|
|
44,941
|
|
|
Other
|
(3,592
|
)
|
|
2,421
|
|
|
Net cash provided by operating activities
|
160,244
|
|
|
132,188
|
|
|
Cash flows from investing activities:
|
|
|
|
|||
Purchase of property and equipment
|
(55,513
|
)
|
|
(28,212
|
)
|
|
Proceeds from sale of property and equipment
|
1,267
|
|
|
985
|
|
|
Net increase in marketable securities
|
(63
|
)
|
|
(29
|
)
|
|
Increase in other assets
|
(3
|
)
|
|
(57
|
)
|
|
Net cash used in investing activities
|
(54,312
|
)
|
|
(27,313
|
)
|
|
Cash flows from financing activities:
|
|
|
|
|||
Borrowings under line of credit
|
20,000
|
|
|
—
|
|
|
Payments against line of credit
|
(20,000
|
)
|
|
—
|
|
|
Proceeds from exercise of stock options
|
2,821
|
|
|
18,285
|
|
|
Excess tax benefits from stock based compensation
|
954
|
|
|
7,697
|
|
|
Payment of dividends
|
(29,662
|
)
|
|
(50,197
|
)
|
|
Net cash used in financing activities
|
(25,887
|
)
|
|
(24,215
|
)
|
|
|
|
|
|
|||
Effect of exchange rate changes on cash
|
(416
|
)
|
|
542
|
|
|
Net increase in cash and cash equivalents
|
79,629
|
|
|
81,202
|
|
|
Cash and cash equivalents at beginning of period
|
79,611
|
|
|
117,676
|
|
|
Cash and cash equivalents at end of period
|
$
|
159,240
|
|
|
198,878
|
|
Supplemental disclosure of cash flow information:
|
|
|
|
|||
Cash paid during each period for interest
|
$
|
34
|
|
|
—
|
|
Cash paid during each period for income taxes
|
$
|
6,502
|
|
|
21,828
|
|
•
|
Level 1 inputs are observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
|
•
|
Level 2 inputs include other inputs that are directly or indirectly observable in the marketplace.
|
•
|
Level 3 inputs are unobservable inputs which are supported by little or no market activity.
|
March 31, 2013:
|
Total
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|||||
Common stock
|
$
|
417
|
|
|
417
|
|
|
—
|
|
|
—
|
|
Total available-for-sale securities
|
$
|
417
|
|
|
417
|
|
|
—
|
|
|
—
|
|
December 31, 2012:
|
Total
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|||||
Common stock
|
$
|
354
|
|
|
354
|
|
|
—
|
|
|
—
|
|
Total available-for-sale securities
|
$
|
354
|
|
|
354
|
|
|
—
|
|
|
—
|
|
March 31, 2012:
|
Total
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|||||
Common stock
|
$
|
347
|
|
|
347
|
|
|
—
|
|
|
—
|
|
Government and agency securities
|
26,847
|
|
|
26,847
|
|
|
—
|
|
|
—
|
|
|
Total available-for-sale securities
|
$
|
27,194
|
|
|
27,194
|
|
|
—
|
|
|
—
|
|
March 31, 2013:
|
Amortized
cost |
|
Gross
unrealized gains |
|
Gross
unrealized losses |
|
Fair value
|
|||||
Common stock
|
$
|
197
|
|
|
220
|
|
|
—
|
|
|
417
|
|
Total available-for-sale securities
|
$
|
197
|
|
|
220
|
|
|
—
|
|
|
417
|
|
December 31, 2012:
|
Amortized
cost |
|
Gross
unrealized gains |
|
Gross
unrealized losses |
|
Fair value
|
|||||
Common stock
|
$
|
197
|
|
|
157
|
|
|
—
|
|
|
354
|
|
Total available-for-sale securities
|
$
|
197
|
|
|
157
|
|
|
—
|
|
|
354
|
|
March 31, 2012:
|
Amortized
cost |
|
Gross
unrealized gains |
|
Gross
unrealized losses |
|
Fair value
|
|||||
Common stock
|
$
|
197
|
|
|
150
|
|
|
—
|
|
|
347
|
|
Government and agency securities
|
26,857
|
|
|
—
|
|
|
(10
|
)
|
|
26,847
|
|
|
Total available-for-sale securities
|
$
|
27,054
|
|
|
150
|
|
|
(10
|
)
|
|
27,194
|
|
|
Less than 12 months
|
|
Greater than 12 months
|
|||||||||
March 31, 2013:
|
Amortized
cost |
|
Fair
value |
|
Amortized
cost |
|
Fair
value |
|||||
Common stock
|
$
|
197
|
|
|
417
|
|
|
—
|
|
|
—
|
|
Total available-for-sale securities
|
$
|
197
|
|
|
417
|
|
|
—
|
|
|
—
|
|
|
Par Value
|
|
March 31,
2013 |
|
December 31,
2012 |
|
March 31,
2012 |
||||
Preferred Stock
|
$.01
|
/share
|
|
|
|
|
|
|
|||
Shares authorized
|
|
|
5,000,000
|
|
|
5,000,000
|
|
|
5,000,000
|
|
|
Shares issued and outstanding
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Common Stock
|
$.01
|
/share
|
|
|
|
|
|
|
|||
Shares authorized
|
|
|
400,000,000
|
|
|
400,000,000
|
|
|
400,000,000
|
|
|
Shares issued and outstanding
|
|
|
296,686,427
|
|
|
296,564,382
|
|
|
296,071,374
|
|
|
2013
|
|
2012
|
|||
First quarter
|
$
|
0.10
|
|
|
0.17
|
|
Second quarter
|
$
|
0.20
|
|
|
0.17
|
|
Third quarter
|
|
|
|
0.19
|
|
|
Fourth quarter
|
|
|
|
0.21
|
|
|
Supplemental
|
|
|
|
0.50
|
|
|
Total
|
$
|
0.30
|
|
|
1.24
|
|
|
|
|
Option
|
|
Closing
|
|
|
|
|
|||||||
|
|
|
exercise
|
|
stock price
|
|
March 31, 2013
|
|||||||||
|
Options
|
|
(strike)
|
|
on date
|
|
Options
|
|
Options
|
|||||||
Date of grant
|
granted
|
|
price
|
|
of grant
|
|
outstanding
|
|
vested
|
|||||||
April 17, 2012
|
1,235,000
|
|
|
$
|
54.00
|
|
|
$
|
49.01
|
|
|
1,152,500
|
|
|
—
|
|
April 19, 2011
|
410,000
|
|
|
$
|
35.00
|
|
|
$
|
31.78
|
|
|
370,000
|
|
|
—
|
|
April 20, 2010
|
530,000
|
|
|
$
|
30.00
|
|
|
$
|
27.13
|
|
|
330,000
|
|
|
—
|
|
April 21, 2009
|
790,000
|
|
|
$
|
27.00
|
|
|
$
|
17.61
|
|
|
520,000
|
|
|
—
|
|
April 15, 2008
|
550,000
|
|
|
$
|
27.00
|
|
|
$
|
24.35
|
|
|
254,417
|
|
|
99,417
|
|
April 17, 2007
|
4,380,000
|
|
|
$
|
22.50
|
|
|
$
|
20.15
|
|
|
1,963,080
|
|
|
947,330
|
|
Total
|
7,895,000
|
|
|
|
|
|
|
4,589,997
|
|
|
1,046,747
|
|
Date of grant
|
Risk-free
interest rate
|
|
Expected life of
option in years
|
|
Expected
dividend
yield
|
|
Expected
stock
volatility
|
|
Estimated fair
value of stock
option
|
|||||
April 17, 2012
|
0.9
|
%
|
|
5.00
|
|
1.4
|
%
|
|
39.25
|
%
|
|
$
|
13.69
|
|
April 19, 2011
|
2.1
|
%
|
|
5.00
|
|
1.6
|
%
|
|
39.33
|
%
|
|
$
|
11.20
|
|
April 20, 2010
|
2.6
|
%
|
|
5.00
|
|
1.5
|
%
|
|
39.10
|
%
|
|
$
|
8.14
|
|
April 21, 2009
|
1.9
|
%
|
|
5.00
|
|
1.0
|
%
|
|
38.80
|
%
|
|
$
|
3.64
|
|
April 15, 2008
|
2.7
|
%
|
|
5.00
|
|
1.0
|
%
|
|
30.93
|
%
|
|
$
|
7.75
|
|
April 17, 2007
|
4.6
|
%
|
|
4.85
|
|
1.0
|
%
|
|
31.59
|
%
|
|
$
|
5.63
|
|
|
Three-month period
|
||||
Reconciliation
|
2013
|
|
2012
|
||
Basic weighted average shares outstanding
|
296,643,014
|
|
|
295,538,402
|
|
Weighted shares assumed upon exercise of stock options
|
1,008,946
|
|
|
1,388,821
|
|
Diluted weighted average shares outstanding
|
297,651,960
|
|
|
296,927,223
|
|
|
Three-month period
|
||||
Summary of anti-dilutive options excluded
|
2013
|
|
2012
|
||
Options to purchase shares of common stock
|
1,168,083
|
|
|
—
|
|
Weighted average exercise price of options
|
$54.00
|
|
$0.00
|
1.
|
Monthly sales changes, sequential trends, and end market performance
– a recap of our recent sales trends and some insight into the activities with different end markets.
|
2.
|
Growth drivers of our business
– a recap of how we grow our business.
|
3.
|
Profit drivers of our business
– a recap of how we increase our profits.
|
4.
|
Statement of earnings information
– a recap of the components of our income statement.
|
5.
|
Operational working capital, balance sheet, and cash flow
– a recap of the operational working capital utilized in our business, and the related cash flow.
|
|
Three-month period
|
|||||
|
2013
|
|
2012
|
|||
Net sales
|
$
|
806,326
|
|
|
768,875
|
|
Percentage change
|
4.9
|
%
|
|
20.0
|
%
|
|
Three-month period
|
||||
|
2013
|
|
2012
|
||
Store Age
|
|
|
|
||
Opened greater than 2 years
|
4.8
|
%
|
|
17.4
|
%
|
Opened greater than 5 years
|
3.6
|
%
|
|
16.2
|
%
|
Opened greater than 10 years
|
1.9
|
%
|
|
14.4
|
%
|
|
Three-month period
|
||||
|
2013
|
|
2012
|
||
Fastener product line
|
43.0
|
%
|
|
45.5
|
%
|
Other product lines
|
57.0
|
%
|
|
54.5
|
%
|
|
100.0
|
%
|
|
100.0
|
%
|
|
Jan.
|
|
Feb.
|
|
Mar.
|
|
Apr.
|
|
May
|
|
June
|
|
July
|
|
Aug.
|
|
Sept.
|
|
Oct.
|
|
Nov.
|
|
Dec.
|
||||||||||||
2013
|
6.7
|
%
|
|
8.2
|
%
|
|
5.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2012
|
21.3
|
%
|
|
20.0
|
%
|
|
19.3
|
%
|
|
17.3
|
%
|
|
13.1
|
%
|
|
14.0
|
%
|
|
12.1
|
%
|
|
12.0
|
%
|
|
12.9
|
%
|
|
6.8
|
%
|
|
8.2
|
%
|
|
9.7
|
%
|
2011
|
18.8
|
%
|
|
21.5
|
%
|
|
22.8
|
%
|
|
23.2
|
%
|
|
22.6
|
%
|
|
22.5
|
%
|
|
22.4
|
%
|
|
20.0
|
%
|
|
18.8
|
%
|
|
21.4
|
%
|
|
22.2
|
%
|
|
21.2
|
%
|
|
Jan.
|
|
Feb.
|
|
Mar.
|
|
Apr.
|
|
May
|
|
June
|
|
July
|
|
Aug.
|
|
Sept.
|
|
Oct.
|
|
Nov.
|
|
Dec.
|
||||||||||||
2013
|
5.0
|
%
|
|
6.5
|
%
|
|
3.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2012
|
18.8
|
%
|
|
17.1
|
%
|
|
16.8
|
%
|
|
14.5
|
%
|
|
10.1
|
%
|
|
11.1
|
%
|
|
9.1
|
%
|
|
8.6
|
%
|
|
9.8
|
%
|
|
3.8
|
%
|
|
5.1
|
%
|
|
6.6
|
%
|
2011
|
16.0
|
%
|
|
18.4
|
%
|
|
19.4
|
%
|
|
19.6
|
%
|
|
19.2
|
%
|
|
19.1
|
%
|
|
18.7
|
%
|
|
16.5
|
%
|
|
15.2
|
%
|
|
18.0
|
%
|
|
18.5
|
%
|
|
17.5
|
%
|
|
Jan.
|
|
Feb.
|
|
Mar.
|
|
Apr.
|
|
May
|
|
June
|
|
July
|
|
Aug.
|
|
Sept.
|
|
Oct.
|
|
Nov.
|
|
Dec.
|
||||||||||||
2013
|
3.2
|
%
|
|
5.6
|
%
|
|
2.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2012
|
17.4
|
%
|
|
15.8
|
%
|
|
15.7
|
%
|
|
13.7
|
%
|
|
9.0
|
%
|
|
10.2
|
%
|
|
8.3
|
%
|
|
7.9
|
%
|
|
8.5
|
%
|
|
2.6
|
%
|
|
4.6
|
%
|
|
5.6
|
%
|
2011
|
15.3
|
%
|
|
17.9
|
%
|
|
19.2
|
%
|
|
19.1
|
%
|
|
17.9
|
%
|
|
18.2
|
%
|
|
17.3
|
%
|
|
15.2
|
%
|
|
14.5
|
%
|
|
17.0
|
%
|
|
17.4
|
%
|
|
16.9
|
%
|
|
Jan.(1)
|
|
Feb.
|
|
Mar.
|
|
Apr.
|
|
May
|
|
June
|
|
July
|
|
Aug.
|
|
Sept.
|
|
Oct.
|
|
Cumulative change
from Jan. to Mar.
|
|||||||||||
Past
|
0.9
|
%
|
|
3.3
|
%
|
|
2.9
|
%
|
|
-0.3
|
%
|
|
3.4
|
%
|
|
2.8
|
%
|
|
-2.3
|
%
|
|
2.6
|
%
|
|
2.6
|
%
|
|
-0.7
|
%
|
|
6.2
|
%
|
2013
|
-0.4
|
%
|
|
2.0
|
%
|
|
3.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.4
|
%
|
|||||||
13Delta
|
-1.3
|
%
|
|
-1.3
|
%
|
|
0.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-0.8
|
%
|
|||||||
2012
|
-0.3
|
%
|
|
0.5
|
%
|
|
6.4
|
%
|
|
-0.8
|
%
|
|
0.5
|
%
|
|
2.5
|
%
|
|
-2.7
|
%
|
|
1.3
|
%
|
|
4.3
|
%
|
|
-4.8
|
%
|
|
7.0
|
%
|
12Delta
|
-1.2
|
%
|
|
-2.8
|
%
|
|
3.5
|
%
|
|
-0.5
|
%
|
|
-2.9
|
%
|
|
-0.3
|
%
|
|
-0.4
|
%
|
|
-1.3
|
%
|
|
1.7
|
%
|
|
-4.1
|
%
|
|
0.8
|
%
|
2011
|
-0.2
|
%
|
|
1.6
|
%
|
|
7.0
|
%
|
|
0.9
|
%
|
|
4.3
|
%
|
|
1.7
|
%
|
|
-1.0
|
%
|
|
1.4
|
%
|
|
3.4
|
%
|
|
0.7
|
%
|
|
8.7
|
%
|
11Delta
|
-1.1
|
%
|
|
-1.7
|
%
|
|
4.1
|
%
|
|
1.2
|
%
|
|
0.9
|
%
|
|
-1.1
|
%
|
|
1.3
|
%
|
|
-1.2
|
%
|
|
0.8
|
%
|
|
1.4
|
%
|
|
2.5
|
%
|
(1)
|
The January figures represent the percentage change from the previous October, whereas the remaining figures represent the percentage change from the previous month.
|
|
Q1
|
|
Q2
|
|
Q3
|
|
Q4
|
|
Annual
|
|||||
2013
|
7.0
|
%
|
|
|
|
|
|
|
|
|
||||
2012
|
20.3
|
%
|
|
15.8
|
%
|
|
14.0
|
%
|
|
9.7
|
%
|
|
14.9
|
%
|
2011
|
15.5
|
%
|
|
18.5
|
%
|
|
18.3
|
%
|
|
21.0
|
%
|
|
20.0
|
%
|
|
Q1
|
|
Q2
|
|
Q3
|
|
Q4
|
|
Annual
|
|||||
2013
|
1.7
|
%
|
|
|
|
|
|
|
|
|
||||
2012
|
15.4
|
%
|
|
8.0
|
%
|
|
6.0
|
%
|
|
2.6
|
%
|
|
7.8
|
%
|
2011
|
15.4
|
%
|
|
18.1
|
%
|
|
13.6
|
%
|
|
15.9
|
%
|
|
15.7
|
%
|
|
Q1
|
|
Q2
|
|
Q3
|
|
Q4
|
|
Annual
|
|||||
2013
|
10.8
|
%
|
|
|
|
|
|
|
|
|
||||
2012
|
25.1
|
%
|
|
21.1
|
%
|
|
18.0
|
%
|
|
13.6
|
%
|
|
19.2
|
%
|
2011
|
26.5
|
%
|
|
27.3
|
%
|
|
26.9
|
%
|
|
27.4
|
%
|
|
27.0
|
%
|
|
Jan.
|
|
Feb.
|
|
Mar.
|
|
Apr.
|
|
May
|
|
June
|
|
July
|
|
Aug.
|
|
Sept.
|
|
Oct.
|
|
Nov.
|
|
Dec.
|
||||||||||||
2013
|
53.1
|
|
|
54.2
|
|
|
51.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
2012
|
53.7
|
|
|
51.9
|
|
|
53.3
|
|
|
54.1
|
|
|
52.5
|
|
|
50.2
|
|
|
50.5
|
|
|
50.7
|
|
|
51.6
|
|
|
51.7
|
|
|
49.9
|
|
|
50.2
|
|
2011
|
59.2
|
|
|
59.6
|
|
|
59.3
|
|
|
59.4
|
|
|
53.5
|
|
|
55.8
|
|
|
52.3
|
|
|
53.2
|
|
|
53.2
|
|
|
51.5
|
|
|
52.3
|
|
|
52.9
|
|
|
Q1
|
|
Q2
|
|
Q3
|
|
Q4
|
|
Annual
|
|||||
2013
|
2.9
|
%
|
|
|
|
|
|
|
|
|
||||
2012
|
17.1
|
%
|
|
12.7
|
%
|
|
8.2
|
%
|
|
4.2
|
%
|
|
10.3
|
%
|
2011
|
17.7
|
%
|
|
15.8
|
%
|
|
15.8
|
%
|
|
17.4
|
%
|
|
17.1
|
%
|
|
|
|
Q1
|
|
Q2
|
|
Q3
|
|
Q4
|
|
Annual
|
|||||
Number of vending machines in
|
2013
|
|
5,728
|
|
|
|
|
|
|
|
|
|
||||
contracts signed during the period
1
|
2012
|
|
4,568
|
|
|
4,669
|
|
|
5,334
|
|
|
5,591
|
|
|
20,162
|
|
|
2011
|
|
1,405
|
|
|
2,107
|
|
|
2,246
|
|
|
2,084
|
|
|
7,842
|
|
Cumulative machines installed
2
|
2013
|
|
25,447
|
|
|
|
|
|
|
|
|
|
||||
|
2012
|
|
9,798
|
|
|
13,036
|
|
|
17,013
|
|
|
21,095
|
|
|
|
|
|
2011
|
|
2,659
|
|
|
3,867
|
|
|
5,642
|
|
|
7,453
|
|
|
|
|
Percent of installed machines that are a FAST 5000
|
2013
|
|
54.3
|
%
|
|
|
|
|
|
|
|
|
||||
(our most common helix vending machine)
3
|
2012
|
|
70.1
|
%
|
|
66.2
|
%
|
|
60.2
|
%
|
|
57.2
|
%
|
|
|
|
|
2011
|
|
78.6
|
%
|
|
76.0
|
%
|
|
74.7
|
%
|
|
72.8
|
%
|
|
|
|
Percent of total net sales to
|
2013
|
|
27.5
|
%
|
|
|
|
|
|
|
|
|
||||
customers with vending machines
4
|
2012
|
|
17.8
|
%
|
|
20.8
|
%
|
|
23.2
|
%
|
|
25.8
|
%
|
|
|
|
|
2011
|
|
8.9
|
%
|
|
10.5
|
%
|
|
13.1
|
%
|
|
15.7
|
%
|
|
|
|
Daily sales growth to customers
|
2013
|
|
23.9
|
%
|
|
|
|
|
|
|
|
|
||||
with vending machines
5
|
2012
|
|
33.9
|
%
|
|
34.3
|
%
|
|
32.9
|
%
|
|
28.6
|
%
|
|
|
|
|
2011
|
|
50.6
|
%
|
|
43.9
|
%
|
|
42.5
|
%
|
|
40.7
|
%
|
|
|
1
|
This represents the gross number of machines signed during the quarter, not the number of contracts.
|
2
|
This represents the number of machines installed and dispensing product on the last day of the quarter.
|
3
|
This information is intended to highlight the mix change in the machines deployed as our business expands beyond the flagship FAST 5000 machine.
|
4
|
The percentage of total sales (vended and traditional) to customers currently using a vending solution.
|
5
|
The growth in total sales (vended and traditional) to customers currently using a vending solution compared to the same period in the preceding year.
|
Sales per Month
|
Average
Age
(Years)
|
|
Number of
Stores
|
|
Percentage
of Stores
|
|
Pre-Tax
Earnings
Percentage
|
||||
Three months ended March 31, 2013
|
|
|
|
|
|
|
Average store sales = $88,267
|
||||
$0 to $30,000
|
5.4
|
|
|
261
|
|
|
9.8
|
%
|
|
-11.6
|
%
|
$30,001 to $60,000
|
8.2
|
|
|
771
|
|
|
29.0
|
%
|
|
13.9
|
%
|
$60,001 to $100,000
|
10.9
|
|
|
765
|
|
|
28.8
|
%
|
|
22.5
|
%
|
$100,001 to $150,000
|
12.8
|
|
|
437
|
|
|
16.4
|
%
|
|
25.5
|
%
|
Over $150,000
|
16.0
|
|
|
305
|
|
|
11.5
|
%
|
|
29.0
|
%
|
Strategic Account/Overseas Store
|
|
|
121
|
|
|
4.5
|
%
|
|
|
|
|
Company Total
|
|
|
2,660
|
|
|
100.0
|
%
|
|
21.7
|
%
|
|
|
|
|
|
|
|
|
|
||||
Three months ended March 31, 2012
|
|
|
|
|
|
|
Average store sales = $86,449
|
||||
$0 to $30,000
|
4.4
|
|
|
289
|
|
|
11.1
|
%
|
|
-17.4
|
%
|
$30,001 to $60,000
|
7.6
|
|
|
795
|
|
|
30.4
|
%
|
|
11.9
|
%
|
$60,001 to $100,000
|
9.9
|
|
|
719
|
|
|
27.5
|
%
|
|
21.5
|
%
|
$100,001 to $150,000
|
12.5
|
|
|
419
|
|
|
16.0
|
%
|
|
24.9
|
%
|
Over $150,000
|
15.6
|
|
|
287
|
|
|
11.0
|
%
|
|
28.4
|
%
|
Strategic Account/Overseas Store
|
|
|
|
102
|
|
|
3.9
|
%
|
|
|
|
Company Total
|
|
|
2,611
|
|
|
100.0
|
%
|
|
21.0
|
%
|
|
|
|
|
|
|
|
|
|
||||
Three months ended March 31, 2011
|
|
|
|
|
|
|
Average store sales = $74,421
|
||||
$0 to $30,000
|
4.2
|
|
|
397
|
|
|
15.7
|
%
|
|
-12.2
|
%
|
$30,001 to $60,000
|
7.5
|
|
|
874
|
|
|
34.7
|
%
|
|
12.6
|
%
|
$60,001 to $100,000
|
10.2
|
|
|
668
|
|
|
26.5
|
%
|
|
22.2
|
%
|
$100,001 to $150,000
|
12.4
|
|
|
310
|
|
|
12.3
|
%
|
|
25.5
|
%
|
Over $150,000
|
15.7
|
|
|
193
|
|
|
7.7
|
%
|
|
27.5
|
%
|
Strategic Account/Overseas Store
|
|
|
|
80
|
|
|
3.2
|
%
|
|
|
|
Company Total
|
|
|
2,522
|
|
|
100.0
|
%
|
|
20.1
|
%
|
|
Q1
2007 |
|
Q3
2008 |
|
Q1
2012 |
|
Q2
2012 |
|
Q3
2012 |
|
Q4 2012
|
|
Q1 2013
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Total net sales reported
|
$489,157
|
|
$625,037
|
|
$768,875
|
|
$804,890
|
|
$802,577
|
|
$757,235
|
|
$806,326
|
|||||||
Less: Non-store sales (approximate)
|
40,891
|
|
57,267
|
|
92,459
|
|
98,735
|
|
100,124
|
|
95,951
|
|
101,624
|
|||||||
Store net sales (approximate)
|
$448,266
|
|
$567,770
|
|
$676,416
|
|
$706,155
|
|
$702,453
|
|
$661,284
|
|
$704,702
|
|||||||
% change since Q1 2007
|
|
|
26.7
|
%
|
|
50.9
|
%
|
|
57.5
|
%
|
|
56.7
|
%
|
|
47.5
|
%
|
|
57.2
|
%
|
|
% change (twelve months)
|
|
|
17.5
|
%
|
|
20.2
|
%
|
|
14.6
|
%
|
|
10.1
|
%
|
|
8.2
|
%
|
|
4.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Percentage of sales through a store
|
92
|
%
|
|
91
|
%
|
|
88
|
%
|
|
88
|
%
|
|
88
|
%
|
|
87
|
%
|
|
87
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Average monthly sales per store
|
$72
|
|
$82
|
|
$86
|
|
$89
|
|
$88
|
|
$83
|
|
$88
|
|||||||
(using ending store count)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
% change since Q1 2007
|
|
|
|
13.9
|
%
|
|
19.4
|
%
|
|
23.6
|
%
|
|
22.2
|
%
|
|
15.3
|
%
|
|
22.2
|
%
|
% change (twelve months)
|
|
|
|
9.3
|
%
|
|
16.2
|
%
|
|
11.3
|
%
|
|
6.0
|
%
|
|
5.1
|
%
|
|
2.3
|
%
|
|
Q1
2007 |
|
Q3
2008 |
|
Q1
2012 |
|
Q2
2012 |
|
Q3
2012 |
|
Q4 2012
|
|
Q1 2013
|
|||||||
Store locations - quarter end count
|
2,073
|
|
2,300
|
|
2,611
|
|
2,635
|
|
2,650
|
|
2,652
|
|
2,660
|
|||||||
% change since Q1 2007
|
|
|
11.0
|
%
|
|
26.0
|
%
|
|
27.1
|
%
|
|
27.8
|
%
|
|
27.9
|
%
|
|
28.3
|
%
|
|
% change (twelve months)
|
|
|
7.2
|
%
|
|
3.5
|
%
|
|
3.0
|
%
|
|
3.3
|
%
|
|
2.6
|
%
|
|
1.9
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Store personnel - absolute headcount
|
6,849
|
|
9,123
|
|
10,486
|
|
10,637
|
|
10,604
|
|
10,347
|
|
10,108
|
|||||||
% change since Q1 2007
|
|
|
33.2
|
%
|
|
53.1
|
%
|
|
55.3
|
%
|
|
54.8
|
%
|
|
51.1
|
%
|
|
47.6
|
%
|
|
% change (twelve months)
|
|
|
17.9
|
%
|
|
12.2
|
%
|
|
9.3
|
%
|
|
5.4
|
%
|
|
0.2
|
%
|
|
-3.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Store personnel - FTE
|
6,383
|
|
8,280
|
|
8,900
|
|
9,126
|
|
9,244
|
|
9,035
|
|
8,875
|
|||||||
Non-store selling personnel - FTE
|
616
|
|
599
|
|
998
|
|
1,054
|
|
1,066
|
|
1,070
|
|
1,121
|
|||||||
Sub-total of all sales personnel - FTE
|
6,999
|
|
8,879
|
|
9,898
|
|
10,180
|
|
10,310
|
|
10,105
|
|
9,996
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Distribution personnel-FTE
|
1,646
|
|
1,904
|
|
1,815
|
|
1,881
|
|
1,887
|
|
1,872
|
|
1,819
|
|||||||
Manufacturing personnel - FTE
1
|
316
|
|
340
|
|
527
|
|
545
|
|
544
|
|
544
|
|
565
|
|||||||
Administrative personnel-FTE
|
767
|
|
805
|
|
796
|
|
794
|
|
808
|
|
811
|
|
832
|
|||||||
Sub-total of non-sales personnel - FTE
|
2,729
|
|
3,049
|
|
3,138
|
|
3,220
|
|
3,239
|
|
3,227
|
|
3,216
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Total - average FTE headcount
|
9,728
|
|
11,928
|
|
13,036
|
|
13,400
|
|
13,549
|
|
13,332
|
|
13,212
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
% change since Q1 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Store personnel - FTE
|
|
|
29.7
|
%
|
|
39.4
|
%
|
|
43.0
|
%
|
|
44.8
|
%
|
|
41.5
|
%
|
|
39.0
|
%
|
|
Non-store selling personnel - FTE
|
|
|
-2.8
|
%
|
|
62.0
|
%
|
|
71.1
|
%
|
|
73.1
|
%
|
|
73.7
|
%
|
|
82.0
|
%
|
|
Sub-total of all sales personnel - FTE
|
|
|
26.9
|
%
|
|
41.4
|
%
|
|
45.4
|
%
|
|
47.3
|
%
|
|
44.4
|
%
|
|
42.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Distribution personnel-FTE
|
|
|
15.7
|
%
|
|
10.3
|
%
|
|
14.3
|
%
|
|
14.6
|
%
|
|
13.7
|
%
|
|
10.5
|
%
|
|
Manufacturing personnel-FTE
1
|
|
|
7.6
|
%
|
|
66.8
|
%
|
|
72.5
|
%
|
|
72.2
|
%
|
|
72.2
|
%
|
|
78.8
|
%
|
|
Administrative personnel-FTE
|
|
|
5.0
|
%
|
|
3.8
|
%
|
|
3.5
|
%
|
|
5.3
|
%
|
|
5.7
|
%
|
|
8.5
|
%
|
|
Sub-total of non-sales personnel - FTE
|
|
|
11.7
|
%
|
|
15.0
|
%
|
|
18.0
|
%
|
|
18.7
|
%
|
|
18.2
|
%
|
|
17.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Total - average FTE headcount
|
|
|
|
22.6
|
%
|
|
34.0
|
%
|
|
37.7
|
%
|
|
39.3
|
%
|
|
37.0
|
%
|
|
35.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
% change (twelve months)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Store personnel - FTE
|
|
|
15.2
|
%
|
|
13.7
|
%
|
|
10.6
|
%
|
|
7.1
|
%
|
|
4.0
|
%
|
|
-0.3
|
%
|
|
Non-store selling personnel - FTE
|
|
|
-2.4
|
%
|
|
28.1
|
%
|
|
24.0
|
%
|
|
15.9
|
%
|
|
12.3
|
%
|
|
12.3
|
%
|
|
Sub-total of all sales personnel - FTE
|
|
|
13.8
|
%
|
|
15.0
|
%
|
|
11.8
|
%
|
|
8.0
|
%
|
|
4.9
|
%
|
|
1.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Distribution personnel-FTE
|
|
|
6.0
|
%
|
|
12.9
|
%
|
|
7.1
|
%
|
|
3.1
|
%
|
|
2.9
|
%
|
|
0.2
|
%
|
|
Manufacturing personnel - FTE
1
|
|
|
1.8
|
%
|
|
14.3
|
%
|
|
10.8
|
%
|
|
6.0
|
%
|
|
5.4
|
%
|
|
7.2
|
%
|
|
Administrative personnel - FTE
|
|
|
7.9
|
%
|
|
4.7
|
%
|
|
1.4
|
%
|
|
-0.4
|
%
|
|
1.9
|
%
|
|
4.5
|
%
|
|
Sub-total of non-sales personnel - FTE
|
|
|
6.0
|
%
|
|
10.9
|
%
|
|
6.2
|
%
|
|
2.7
|
%
|
|
3.0
|
%
|
|
2.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Total - average FTE headcount
|
|
|
11.7
|
%
|
|
14.0
|
%
|
|
10.4
|
%
|
|
6.7
|
%
|
|
4.4
|
%
|
|
1.4
|
%
|
1
|
The manufacturing headcount was impacted by the addition of 92 employees with the acquisition of Holo-Krome in December 2009.
|
STATEMENT OF EARNINGS INFORMATION (percentage of net sales)
for the periods ended March 31:
|
|||||
|
|
||||
|
Three-month period
|
||||
|
2013
|
|
2012
|
||
Net sales
|
100.0
|
%
|
|
100.0
|
%
|
Gross profit
|
52.3
|
%
|
|
51.3
|
%
|
Operating and administrative expenses
|
30.7
|
%
|
|
30.3
|
%
|
(Gain) loss on sale of property and equipment
|
0.0
|
%
|
|
0.0
|
%
|
Operating income
|
21.7
|
%
|
|
20.9
|
%
|
Interest income/expense (net)
|
0.0
|
%
|
|
0.0
|
%
|
Earnings before income taxes
|
21.7
|
%
|
|
21.0
|
%
|
Note – Amounts may not foot due to rounding difference.
|
|
|
|
|
Q1
|
|
Q2
|
|
Q3
|
|
Q4
|
||||
2013
|
52.3
|
%
|
|
|
|
|
|
|
|||
2012
|
51.3
|
%
|
|
51.6
|
%
|
|
51.6
|
%
|
|
51.6
|
%
|
2011
|
52.0
|
%
|
|
52.2
|
%
|
|
51.9
|
%
|
|
51.2
|
%
|
|
Three-month period
|
||||
|
2013
|
|
2012
|
||
Employee related expenses
|
5.5
|
%
|
|
14.9
|
%
|
Occupancy related expenses
|
13.6
|
%
|
|
0.3
|
%
|
Selling transportation costs
|
0.9
|
%
|
|
19.3
|
%
|
Per gallon average price
|
|
Q1
|
|
Q2
|
|
Q3
|
|
Q4
|
|
Annual
Average
1
|
||||||
|
|
|
|
|
|
|
|
|
|
|
||||||
2013 price
|
|
|
|
|
|
|
|
|
|
|
||||||
Diesel fuel
|
|
$
|
4.02
|
|
|
|
|
|
|
|
|
|
|
|
||
Gasoline
|
|
$
|
3.51
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
||||||
2012 price
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diesel fuel
|
|
$
|
3.92
|
|
|
3.98
|
|
|
3.88
|
|
|
4.05
|
|
|
3.96
|
|
Gasoline
|
|
$
|
3.53
|
|
|
3.73
|
|
|
3.61
|
|
|
3.53
|
|
|
3.60
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
2011 price
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diesel fuel
|
|
$
|
3.60
|
|
|
4.04
|
|
|
3.90
|
|
|
3.87
|
|
|
3.85
|
|
Gasoline
|
|
$
|
3.22
|
|
|
3.78
|
|
|
3.62
|
|
|
3.37
|
|
|
3.50
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Per gallon price change
|
|
Q1
|
|
Q2
|
|
Q3
|
|
Q4
|
|
Annual
1
|
||||||
|
|
|
|
|
|
|
|
|
|
|
||||||
2013 change
|
|
|
|
|
|
|
|
|
|
|
||||||
Diesel fuel
|
|
2.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gasoline
|
|
-0.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
2012 change
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diesel fuel
|
|
8.9
|
%
|
|
-1.5
|
%
|
|
-0.5
|
%
|
|
4.7
|
%
|
|
2.9
|
%
|
|
Gasoline
|
|
9.6
|
%
|
|
-1.3
|
%
|
|
-0.3
|
%
|
|
4.7
|
%
|
|
2.9
|
%
|
1
|
Average of the four quarterly figures contained in the table.
|
|
|
Balance at March 31:
|
|
Twelve Month Dollar Change
|
|
Twelve Month Percentage Change
|
||||||||||||||||
|
|
2013
|
|
2012
|
|
2011
|
|
2013
|
|
2012
|
|
2013
|
|
2012
|
||||||||
Accounts receivable, net
|
|
$
|
418,733
|
|
|
386,882
|
|
|
325,685
|
|
|
31,851
|
|
|
61,197
|
|
|
8.2
|
%
|
|
18.8
|
%
|
Inventories
|
|
$
|
700,484
|
|
|
647,886
|
|
|
576,451
|
|
|
52,598
|
|
|
71,435
|
|
|
8.1
|
%
|
|
12.4
|
%
|
Operational working capital
1
|
|
$
|
1,119,217
|
|
|
1,034,768
|
|
|
902,136
|
|
|
84,449
|
|
|
132,632
|
|
|
8.2
|
%
|
|
14.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Sales in last two months
|
|
$
|
531,460
|
|
|
522,905
|
|
|
437,773
|
|
|
8,555
|
|
|
85,132
|
|
|
1.6
|
%
|
|
19.4
|
%
|
|
Three-month period
|
|||||
|
2013
|
|
2012
|
|||
Net cash provided by operating activities
|
$
|
160,244
|
|
|
132,188
|
|
Net cash used in investing activities
|
$
|
54,312
|
|
|
27,313
|
|
Net cash used in financing activities
|
$
|
25,887
|
|
|
24,215
|
|
|
|
|
|
|||
Net cash provided by operating activities
|
146.9
|
%
|
|
131.9
|
%
|
|
Net cash used in investing activities
|
49.8
|
%
|
|
27.3
|
%
|
|
Net cash used in financing activities
|
23.7
|
%
|
|
24.2
|
%
|
3.1
|
Restated Articles of Incorporation of Fastenal Company, as amended effective as of April 17, 2012 (incorporated by reference to Exhibit 3.1 to Fastenal Company’s Form 10-Q for the quarter ended March 31, 2012)
|
|
|
3.2
|
Restated By-Laws of Fastenal Company (incorporated by reference to Exhibit 3.2 to Fastenal Company’s Form 8-K dated as of October 15, 2010)
|
|
|
31
|
Certifications under Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
32
|
Certification under Section 906 of the Sarbanes-Oxley Act of 2002
|
|
|
101
|
The following financial statements from Fastenal Company’s Quarterly Report on Form 10-Q for the quarter ended March 31. 2013, filed on April 15, 2013, formatted in Extensible Business Reporting Language (XBRL): (i) Consolidated Statements of Earnings, (ii) Consolidated Statements of Comprehensive Income, (iii) Consolidated Balance Sheets, (iv) Consolidated Statements of Cash Flows, and (v) the Notes to Consolidated Financial Statements.
|
|
|
FASTENAL COMPANY
|
|
|
|
|
|
|
|
|
/s/ Willard D. Oberton
|
|
|
(Willard D. Oberton, Chief Executive Officer)
|
|
|
(Duly Authorized Officer)
|
|
|
|
|
|
|
Date April 15, 2013
|
|
/s/ Daniel L. Florness
|
|
|
(Daniel L. Florness, Chief Financial Officer)
|
|
|
(Principal Financial Officer)
|
3.1
|
Restated Articles of Incorporation of Fastenal Company, as amended effective as of April 17, 2012
|
|
(Incorporated by reference)
|
|
|
|
|
3.2
|
Restated By-Laws of Fastenal Company
|
|
(Incorporated by reference)
|
|
|
|
|
31
|
Certifications under Section 302 of the Sarbanes-Oxley Act of 2002
|
|
Electronically Filed
|
|
|
|
|
32
|
Certification under Section 906 of the Sarbanes-Oxley Act of 2002
|
|
Electronically Filed
|
|
|
|
|
101.INS
|
XBRL Instance Document
|
|
Electronically Filed
|
|
|
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
|
Electronically Filed
|
|
|
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
Electronically Filed
|
|
|
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
Electronically Filed
|
|
|
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
Electronically Filed
|
|
|
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
Electronically Filed
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|---|---|---|
Dr. Vandebroek has served as founder and owner of Strategic Vision Ventures, LLC, a technology consulting firm, since 2021. Previously, Dr. Vandebroek was the inaugural visiting scholar at the Massachusetts Institute of Technology School of Engineering for the 2019-2020 academic year; Vice President, Emerging Technology Partnerships for IBM from 2018 to 2019; and Chief Operating Officer - IBM Research from 2017 to 2018. Prior to joining IBM, she was an executive with Xerox Corporation, where her roles included serving as Chief Technology Officer and Corporate Vice President of Xerox Corporation, President of the Xerox Innovation Group, and Chief Engineer. She was also responsible for overseeing Xerox’s global research centers, including the Palo Alto Research Center, or PARC Inc. Dr. Vandebroek currently serves on the boards of IDEXX Laboratories, Inc. and Wolters Kluwer N. V., both of which are publicly traded, as well as Inari Agriculture, Inc., a privately held biotechnology company, and formerly served on the board of Analogic Corporation. In 2021, Dr. Vandebroek was appointed an honorary Professor at KU Leuven, Belgium. Dr. Vandebroek is the Chair of the Advisory Committee of the Flanders AI Research Program and a Fellow of the Institute of Electrical & Electronics Engineers. Dr. Vandebroek holds a bachelor’s degree and a master’s degree in electro-mechanical engineering from KU Leuven, Leuven, Belgium, and a doctoral degree in electrical engineering from Cornell University. | |||
Mr. Chapin retired from Bank of America Merrill Lynch in 2016 as Executive Vice Chairman of Global Corporate & Investment Banking, after more than thirty years in investment banking. As Executive Vice Chairman from 2010 to 2016 he was responsible for managing relationships with some of the firm’s largest clients. Mr. Chapin has worked on a broad range of financings and strategic advisory assignments totaling more than $500 billion and has been named Investment Banker of the Year by Investment Dealers’ Digest . Mr. Chapin was named Vice Chairman of Merrill Lynch & Co., Inc. in 2003 and was a member of the firm’s executive Operating Committee. Mr. Chapin served in a number of other senior leadership positions while at Bank of America Merrill Lynch, including having responsibility for the Global Investment Banking division and managing many of the firm’s global corporate relationships. Mr. Chapin has served since 2019 as a Senior Advisor to Rockefeller Capital Management, a leading independent, privately owned financial services firm. He is also a member of the board of directors of O-I Glass, Inc. and PHINIA, Inc., both of which are publicly traded, and until 2023 was a director of CIRCOR International, Inc. Additionally, he serves as a trustee emeritus of Lafayette College and as a director emeritus of New York’s Roundabout Theatre Company. Mr. Chapin holds a Bachelor of Arts degree from Lafayette College and a Master of Business Administration degree from The Wharton School at the University of Pennsylvania. | |||
Dr. Singh was elected President and Chief Executive Officer of Revvity effective December 30, 2019, and appointed to our board of directors in 2019. Previously, Dr. Singh was the President and Chief Operating Officer of the Company since January 2019. Dr. Singh joined Revvity as the President of our Diagnostics business in 2014. He was elected Senior Vice President in 2016 and Executive Vice President in 2018. Prior to joining Revvity, Dr. Singh was General Manager of GE Healthcare’s Women’s Health business from 2012 to 2014, with responsibility for its mammography and bone densitometry businesses. Before that, Dr. Singh held senior executive level roles in strategy, business development and mergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in his career, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently at Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Middle East region. | |||
Dr. Barrett joined Atlas Venture, an early-stage life sciences venture capital fund, in 2002 and is a partner in the life sciences group, where he has been involved in the creation of several therapeutic and drug discovery platform companies. Previously, he was a co-founder, Executive Vice President and Chief Business Officer of Celera Genomics which in 2001 announced the first successful sequencing of the human genome. Prior to that, Dr. Barrett held several senior management positions at The Perkin-Elmer Corporation, most recently serving as Vice President, Corporate Planning and Business Development, where he operated several businesses and helped to greatly expand its life sciences portfolio through a series of licensing agreements, partnerships and acquisitions. He currently serves as the Chairman of Synlogic, Inc., which is publicly traded, and is a board member of privately held Obsidian Therapeutics, Inc. Dr. Barrett is also an executive fellow at the Harvard Business School and is the chair of the key advisory board of the Blavatnik Fellowship program. Dr. Barrett previously served on the board of Larimar Therapeutics, Inc., a publicly traded company, until 2023. In addition, Dr. Barrett is a board member of Nucleate, a student run non-profit organization representing the global community of bio-innovators. Dr. Barrett received his Bachelor of Science degree in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his doctoral degree in analytical chemistry from Northeastern University. | |||
Ms. Witz has served as the President of PWH Advisors, a consultancy firm advising healthcare and investment companies, since founding the firm in 2016. Previously, Ms. Witz served as a Member of the Executive Committee for Sanofi, S. A., most recently as Executive Vice President, Global Diabetes & Cardiovascular, and previously as Executive Vice President, Global Pharma and Consumer Healthcare divisions. Before joining Sanofi, Ms. Witz served as President and Chief Executive Officer of GE’s pharmaceutical diagnostics, a $2 billion integrated pharmaceutical business that encompassed research and development through commercialization. Previously Ms. Witz served with GE Healthcare, where she held positions of increasing responsibility in Europe and the United States. Before joining GE Healthcare, Ms. Witz was previously employed with Becton Dickinson Pharmaceutical Systems. Ms. Witz currently serves on the boards of publicly traded companies Fresenius Medical Care AG and Regulus Therapeutics, Inc., as well as several privately held companies. Ms. Witz formerly served on the boards of publicly traded Horizon Therapeutics plc until 2023, Savencia SA until 2018, and Tesaro, Inc. until 2019. Ms. Witz received her Master of Business Administration degree from INSEAD, Fontainebleau, France and her Master of Science degree in biochemistry from the Institut National des Sciences Appliquées, Lyon, France. She was also a doctoral student in molecular biology at the Centre National de la Recherche Scientifique, Strasbourg, France. | |||
MICHELLE MCMURRY-HEATH, MD, PhD : Age 55; Principal Occupation: Founder and Chief Executive Officer, BioTechquity Clinical. Director of Revvity since 2022. Member of the compensation and benefits committee. | |||
MICHEL VOUNATSOS : Age 63; Principal Occupation: Former Chief Executive Officer of Biogen Inc. Director of Revvity since 2020. Chair of the nominating and corporate governance committee and member of the audit committee. | |||
Mr. Klobuchar joined Eikon Therapeutics in 2024, and oversees the company’s corporate infrastructure, including global supply chain management and product manufacturing. Mr. Klobuchar is a member of Eikon’s Executive Committee and manages key executives across a variety of functional areas and business operations. Prior to joining Eikon, Mr. Klobuchar had been associated with Merck & Co., Inc., a premier research-intensive global biopharmaceutical company, for over 25 years, most recently serving from 2021 to 2024 as Executive Vice President and Chief Strategy Officer, and from 2019 to 2021 as Senior Vice President, CFO and Head of Portfolio and Alliance Management for Merck Research Laboratories. Prior to that, Mr. Klobuchar held a variety of positions of increasing responsibility in Merck’s research, manufacturing, commercial planning, finance and strategy organizations, including leading key elements related to the integration of Merck Research Laboratories with Schering-Plough R&D following the merger of the two companies. Mr. Klobuchar received his Master of Business Administration degree from Villanova University, a Master of Science degree in chemical engineering from Rutgers University and a Bachelor of Science degree from Purdue University. | |||
FRANK WITNEY, PhD : Age 71; Principal Occupation: Former Chief Executive Officer, Affymetrix, Inc., a leading provider of microarray technology; Director of Revvity since 2016. Member of the compensation and benefits and nominating and corporate governance committees. | |||
Mr. Michas was named Non-Executive Chair of the board as of December 30, 2019. He brings to our board, and to the position of Non-Executive Chair, many years of private equity experience across a wide range of industries, and a successful record of managing investments in public companies. Mr. Michas also brings extensive transactional expertise, including mergers and acquisitions, IPOs, debt and equity offerings, and bank financing. This expertise allows Mr. Michas to provide our board with valuable insight on trends in global debt and equity markets, and the impact of such trends on the capital structure of the Company. We also benefit from the corporate governance knowledge developed by Mr. Michas in his board roles with other public companies, including his service as a board chair, a lead director, and a member of the compensation, governance, audit, finance and executive committees of such companies. Mr. Michas’ thorough knowledge of the Company and his current and past service on the boards of other public companies make him uniquely qualified to serve as our Non-Executive Chair. |
Name and Principal Position |
Year |
Salary
($) |
Bonus
($) |
Stock
Awards ($) |
Option
Awards ($) |
Non-Equity
Incentive Plan Compensation ($) |
All Other
Compensation ($) |
Total ($) | ||||||||||||||||||||||||||||||||
Prahlad R. Singh Chief Executive Officer |
2024 | $ | 1,100,000 | — | $ | 4,125,038 | $ | 4,116,298 | $ | 2,530,440 | $ | 54,839 | $ | 11,926,615 | ||||||||||||||||||||||||||
2023 | $ | 1,086,539 | — | $ | 5,775,022 | $ | 1,921,023 | $ | 315,563 | $ | 32,477 | $ | 9,130,624 | |||||||||||||||||||||||||||
2022 | $ | 1,050,000 | — | $ | 5,512,467 | $ | 1,836,460 | $ | 2,152,763 | $ | 25,309 | $ | 10,576,998 | |||||||||||||||||||||||||||
Maxwell Krakowiak Senior Vice President and Chief Financial Officer
|
2024 | $ | 507,692 | — | $ | 1,050,013 | $ | 1,047,775 | $ | 615,038 | $ | 25,168 | $ | 3,245,686 | ||||||||||||||||||||||||||
2023 | $ | 500,000 | — | $ | 1,468,779 | $ | 654,938 | $ | 111,563 | $ | 19,548 | $ | 2,754,828 | |||||||||||||||||||||||||||
2022 | $ | 365,124 | $ | 50,000 | $ | 324,899 | $ | 324,955 | $ | 383,210 | $ | 16,250 | $ | 1,464,439 | ||||||||||||||||||||||||||
Joel S. Goldberg Senior Vice President, Administration, General Counsel and Secretary
|
2024 | $ | 550,000 | — | $ | 1,031,208 | $ | 1,029,084 | $ | 732,188 | $ | 39,086 | $ | 3,381,566 | ||||||||||||||||||||||||||
2023 | $ | 547,308 | — | $ | 1,443,756 | $ | 480,244 | $ | 122,719 | $ | 50,715 | $ | 2,644,742 | |||||||||||||||||||||||||||
2022 | $ | 538,115 | — | $ | 1,214,971 | $ | 404,768 | $ | 703,688 | $ | 44,015 | $ | 2,905,558 | |||||||||||||||||||||||||||
Miriame Victor Senior Vice President and Chief Commercial Officer
|
2024 | $ | 467,692 | — | $ | 727,508 | $ | 725,981 | $ | 530,299 | $ | 26,166 | $ | 2,477,646 | ||||||||||||||||||||||||||
2023 | $ | 447,077 | — | $ | 862,557 | $ | 286,903 | $ | 83,870 | $ | 24,450 | $ | 1,704,856 | |||||||||||||||||||||||||||
Tajinder S. Vohra Senior Vice President Global Operations
|
2024 | $ | 475,000 | — | $ | 653,115 | $ | 651,738 | $ | 504,189 | $ | 25,311 | $ | 2,309,353 | ||||||||||||||||||||||||||
2023 | $ | 470,962 | — | $ | 890,613 | $ | 296,287 | $ | 79,943 | $ | 23,170 | $ | 1,760,975 | |||||||||||||||||||||||||||
2022 | $ | 451,923 | — | $ | 689,905 | $ | 229,892 | $ | 452,695 | $ | 22,623 | $ | 1,847,038 |
Customers
Customer name | Ticker |
---|---|
Target Corporation | TGT |
No Suppliers Found
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|---|---|---|
Singh Prahlad R. | - | 90,195 | 37,163 |
Singh Prahlad R. | - | 83,016 | 25,088 |
MICHAS ALEXIS P | - | 58,203 | 500 |
Goldberg Joel S | - | 33,400 | 63,709 |
Goldberg Joel S | - | 27,319 | 63,709 |
Vohra Tajinder S | - | 22,625 | 0 |
Witney Frank | - | 18,662 | 0 |
Witz Pascale | - | 13,705 | 0 |
Tereau Daniel R | - | 11,611 | 0 |
Krakowiak Maxwell | - | 7,202 | 0 |
Victor Miriame | - | 6,960 | 0 |
Gonzales Anita | - | 4,522 | 0 |
Okun Andrew | - | 4,356 | 8 |
Gonzales Anita | - | 3,859 | 0 |
McMurry-Heath Michelle | - | 3,021 | 0 |
Vandebroek Sophie V. | - | 481 | 0 |